Caplin Point Laboratories Limited — Q3 FY26
Caplin Point reported a steady Q3 FY26 with 10.6% YoY revenue growth and 28.3% PAT margin, driven by strong US sterile injectable approvals and disciplined cost management.
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
50%Questions answered2Evaded / deflected10Questions audited
Evasive
High priority
Why is the oncology facility delayed again from Q1 FY27 to Q3 FY27?
Asked by CA Gervid Goyel, Serene Alpha
Management acknowledged delay but did not explain root cause, instead pivoted to facility readiness and ecosystem challenges.
reframed the questionno specific reason givenblamed ecosystem
Read the exchange
Question
First question is on onology KPI facility. It is getting further delayed sir. Earlier we were speaking about Q1 27 and this PP we have mentioned Q3 27.
Chairman (name not stated)
Delay yes it happened but in the current context what is important actually is not the delay is not totally denied actually it's not a denied opportunity today it is fully completed...
Partial answer
High priority
Why is top-line growth slowing despite doubling fixed assets?
Asked by CA Gervid Goyel, Serene Alpha
Management reiterated consolidation phase but did not quantify when growth would re-accelerate or address asset turnover.
no specific timeline for ramp-updeferred to future
Read the exchange
Question
First 9 months our sales are up by 10 to 11% whereas which is well below our last three year average of 15%... even if I CEO fixed assets these have doubled in last 2 and a half to three years but our top line is up by only 40 50% against that so why are we slowing growing our top line?
Management (likely Vice Chairman or CEO, name not stated)
We've been very consistent with our messaging that the next 18 to 24 months is going to be a gestation and consolidation phase for us... our US business which is gaining much more traction is showing growth of almost 25 30% also.
Partial answer
Medium priority
Is there further scope for margin improvement?
Asked by CA Gervid Goyel, Serene Alpha
Management gave a range but did not commit to a specific improvement timeline or quantify potential upside.
no specific margin target givenvague on timing
Read the exchange
Question
Regarding on the margins front is there any further scope of improvement in the margins?
Management (likely Vice Chairman or CEO)
I think we're at a path of 27 28%. I'm not sure if there are too many peers within this range... once we start firing on these newer initiatives there is a potential for that to go up as well.
Partial answer
High priority
What was paid for oncology ANDAs, timelines, and market share potential?
Asked by Ahmed Madha, Unifi Capital
Management refused to disclose acquisition cost but provided a clue and gave timelines and market share expectations.
declined to give pricegave indirect clue only
Read the exchange
Question
The bio we made for few AMDs on the oncology side. If you can give some sense what amount we have paid for the ANDDS... what will be the timelines do the site transfer and the commercialization take and from the $473 million addressable market size what sort of potential market share can Kapalene sterile gain?
Management (likely Vice Chairman or CEO)
Some of this information is of confidential nature. So I won't be able to go into too much details... any acquisition of an ANDA that we do is always equal to or lower than the cost of actually filing that and itself.
Answered
High priority
How far from meaningful topline in Mexico and Chile?
Asked by Ahmed Madha, Unifi Capital
Management gave a clear timeline of 18-24 months for meaningful revenue generation.
Read the exchange
Question
On the Mexico and Chile business... can give some sense how far are we from meaningful topline generation from those markets and what sort of progress we have made in terms of commercialization?
Management (likely Vice Chairman or CEO)
When it comes to again Mexico and Chile, I would still put the same timelines. At about 18 to 24 months is when we can start to see it firing on all cylinders.
Partial answer
Medium priority
Why are operating costs stable despite new plants and topline growth?
Asked by Ahmed Madha, Unifi Capital
CFO's answer was partially inaudible and lacked specific quantification of cost absorption.
audio issuesunclear explanation
Read the exchange
Question
If I look at last year, the operating cost which was apart from the employee cost was about 89 crores. This quarter it is about 88 crores and we have grown topline by 10%age. So broadly the cost are similar... what explains that the costs have not gone up despite topline going up and new plants getting commercialized?
CFO (name not stated)
Couple of years back when we were in the same meeting we were asked for this lower turnover and in return cost he has built the infrastructure they built the as the employees have all been recruited for the enhanced capacity...
Answered
Medium priority
What is the EBITDA for Caplin Steriles?
Asked by Sinja Mittal, MS Capital
Management provided a specific EBITDA number for Caplin Steriles.
Read the exchange
Question
If Mr. Satya you can help me with a scaven sterile number that would be very helpful.
Management (likely Mr. Satya, name not stated)
For the quarter end December 2025 the bida for CSL consolidated is 31.09 crores.
Answered
Low priority
Any material update on inorganic acquisitions?
Asked by CA Gervid Goyel, Serene Alpha
Management clearly stated no material update.
Read the exchange
Question
Is there any further material update on the inotenic acquisitions that we are evaluating right now?
Management (likely Vice Chairman or CEO)
Nothing nothing to report at this point. So if there is something material definitely we will update as and when necessary but nothing is at very late stages or anything like that at this point.
Partial answer
High priority
How much of the Rs 1000 crore capex has been spent and expected asset turns?
Asked by Richa, Equity Masters
CFO provided capex spent details but declined to give asset turn expectations, calling it difficult to predict.
no asset turn guidance given
Read the exchange
Question
Out of the thousand crores of capex expansion that we have taken up how much has been spent already and what is expected to be spent in the next two years. And the last is asset turn?
CFO (name not stated)
What we have capitalized thus far is about 153 crores and 121 crores is in WAP. This is adding up to about 280 290 cr and what we have further advanced about 88.54 crores. About 100 crores 385 crores is already spent. The rest is to be spent in the next over the next 12 to 18 months.
Answered
Low priority
What is the expected tax rate going forward?
Asked by Richa, Equity Masters
CFO gave a clear range for expected tax rate.
Read the exchange
Question
How should we look at the tax rates? Are they going to stay where they are?
CFO (name not stated)
Tax place we have been telling that about we have some revenues and we are at about 20 21%age. We expect that to be around that in the coming years as well.
Evasive
Medium priority
Can you provide Chile market revenues for 9 months?
Asked by Ketan, Individual Investor
Chairman did not provide the requested revenue figure, instead discussed market dynamics and recent private market progress.
did not provide revenue numbergave qualitative update instead
Read the exchange
Question
For the 9 months is it possible to provide the revenues for the Chile market?
Chairman (name not stated)
Chile market what is happening there is as has been so told actually by Ve this is a market where I know it's all tender heavy like 75 to 80% is tender and 20% is private market...
Partial answer
Medium priority
Will US margins inch up in the next few quarters?
Asked by Ketan, Individual Investor
Management gave qualitative optimism but no quantitative margin trajectory for near term.
no specific margin guidancedeferred to 2028
Read the exchange
Question
Right now the margins look about 10 or percent but going forward is this likely to inch up? I mean in terms of the margins for the USA business is it likely to go up in the next few quarters and few years.
Chairman and Vice Chairman/CEO
Coming to business I would like to say something afterwards is it will actually bring the host... when we have 13 14 15 lines your expenses start to cap out after a bit and every additional revenue that you have will be a direct impact to the bottom line positively.